Artrya Limited ( (AU:AYA) ) just unveiled an announcement.
Artrya Limited has achieved a significant milestone by receiving FDA 510(k) clearance for its Salix® Coronary Anatomy, allowing for its commercial sale in the US. This clearance paves the way for its formal launch across US hospital systems. The company has also secured three-year contracts with Sonic Healthcare Australia and Lumus Imaging for the use of its platform. Additionally, Artrya is advancing its clinical validation efforts for other products, including the Salix® Coronary Plaque and Salix® Coronary Flow, in preparation for further FDA submissions. The successful capital raise of $15 million boosts its financial position, supporting ongoing operations and product development.
More about Artrya Limited
Artrya Limited operates in the healthcare industry, focusing on developing innovative medical technologies. The company specializes in coronary artery disease diagnostics, with products like Salix® Coronary Anatomy aimed at improving the detection and management of heart disease.
YTD Price Performance: 19.81%
Average Trading Volume: 271,798
Technical Sentiment Signal: Sell
See more data about AYA stock on TipRanks’ Stock Analysis page.